Oligonucleotides and genes have shown considerable therapeutic potential in model systems. Comparable clinical success is delayed essentially because of their poor bioavailabiltiy, of immune responses against viral vectors or of ineffective intracellular trafficking of synthetic vectors. Advances in the mechanism of nonviral gene delivery (1) (2) (3) (4) (5) provide new ideas for the design of improved supramolecular systems. Moreover, artificial vectors are neither limited to the molecules nor to the solutions found by Evolution to overcome these barriers. Cell-mediated immune response against the vector can thus be avoided.
展开▼
